array(13) { ["code"]=> string(2) "en" ["id"]=> string(1) "1" ["native_name"]=> string(2) "US" ["major"]=> string(1) "1" ["active"]=> string(1) "1" ["default_locale"]=> string(2) "en" ["encode_url"]=> string(1) "0" ["tag"]=> string(2) "en" ["missing"]=> int(0) ["translated_name"]=> string(2) "US" ["url"]=> string(38) "https://www.prosigna.com/en/resources/" ["country_flag_url"]=> string(87) "https://www.prosigna.com/wp-content/plugins/sitepress-multilingual-cms/res/flags/en.png" ["language_code"]=> string(2) "en" } native: US
translated: US
IN the US OUTSIDE the US
CONTACT US

Contact us today

Monday to Friday, 5:30 AM – 5:00 PM (PST)

Phone: 1.888.923.4762

International: +1.650.243.6335

Fax: 650.243.6388

info@prosigna.com

September 27 – 6:00 p.m. CEST / 12:00 p.p. ET: Live educational program on molecular gene expression testing
Register here

PROSIGNA PRODUCT INSERTS AND MSDS

  • Download the Prosigna Product Insert
  • Download the nCounter
    Hybridization Buffer MSDS
  • Download the nCounter Prep
    Plate MSDS
  • Download the nCounter
    Reporter CodeSet MSDS
  • Download the nCounter
    Cartridge MSDS
  • Download the nCounter DX
    Analysis System User Manual
  • Download the Prosigna
    Product Data Sheet

  • Download the RNA Reference Samples and Training Samples Datasheet

Scientific Evidence Of The Prosigna Assay’s Clinical Performance

More comprehensive information for better treatment decisions

  • OPTIMA (Optimal Personalized
    Treatment of early breast cancer using Multi-parameter Analysis) Clinical Trial



  • EXPERT (Examining
    Personalized Radiation Therapy
    for Low-risk Early Breast
    Cancer) Clinical Trial



  • Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
  • Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy



  • Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer





  • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
  • The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer




  • Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
  • PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer


  • Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
  • The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
  • Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype- Prosigna® Test in the management of early-stage breast cancers



  • Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (NICE Diagnostic Guidance)


  • Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
  • Molecular Divers of Onco Type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study


COMMERCIAL LABS

Select one of the nationally accessible labs below to learn more about how you can have the Prosigna breast cancer assay performed on the locally available nCounter Dx Analysis System.  

HEALTH INSURANCE COVERAGE

The Prosigna Breast Cancer Assay is covered by Medicare and commercial payers for patients
meeting the indications for use

To learn more about Prosigna Breast Cancer Assay’s commercial coverage please get in touch with our customer care team or email us at info@prosigna.com.

NEWS

  • Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
  • Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany